#VisualAbstract: Trastuzumab emtansine monotherapy is noninferior to standard neoadjuvant therapy for ERBB2+ breast cancer
Click to read the study in JAMA Oncology.
Click to read the study in JAMA Oncology.
Click to read the study in The Lancet Oncology.
Click to read the study in JAMA Oncology.
Click to read the study in JAMA Network Open
1. In this randomized, placebo controlled study of HER2-positive breast cancer patients receiving trastuzumab, use of preventative lisinopril or carvedilol ...
1. Patients with residual human epidermal growth factor receptor 2 (HER2)-positive breast cancer after chemotherapy and HER2 targeted therapy had ...
Image: PD 1. At 8 years median follow-up, trastuzumab treatment for HER2-positive breast cancer is associated with slightly increased rates ...
Image: PD 1. One year of adjuvant Herceptin (trastuzumab) has similar efficacy as a two-year regimen. 2. One-year regimen was ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.